We are live on ! Find out more
INSY

Insys Therapeutics, Inc.
INSY

Delisted

INSY was delisted on the 18th of June, 2019.

Back to rankings

99 hedge funds and large institutions have $352M invested in Insys Therapeutics, Inc. in 2014 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 39 increasing their positions, 26 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 26

0% more funds holding

Funds holding: 99 → 99 (0)

0% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 28

5% less capital invested

Capital invested by funds: $372M → $352M (-$20.2M)

39% less call options, than puts

Call options by funds: $2.61M | Put options by funds: $4.25M

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
99
Holders Change
–
Holders Change %
0%
% of All Funds
2.85%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.03%
New
28
Increased
39
Reduced
26
Closed
28
Calls
$2.61M
Puts
$4.25M
Net Calls
-$1.65M
Net Calls Change
-$4.32M

Top Buyers

Rank Fund Capital Flow
1
ECP
Empyrean Capital Partners
California
+$25.9M
2
BTP
Bloom Tree Partners
New York
+$25.4M
3
JHIU
Janus Henderson Investors US
Colorado
+$25.1M
4
CCM
Consonance Capital Management
New York
+$12.5M
5
BA
BlackRock Advisors
Delaware
+$8.26M

Top Sellers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
-$21M
2
TCM
Tamarack Capital Management
California
-$19.8M
3
Renaissance Technologies
Renaissance Technologies
New York
-$5.68M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$4.94M
5
Two Sigma Investments
Two Sigma Investments
New York
-$4.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
101
Two Sigma Investments
New York
– -$4.02M -194,114 Closed
CCM
102
Cadence Capital Management
Massachusetts
– -$3.63M -175,040 Closed
NI
103
Numeric Investors
Massachusetts
– -$3.59M -173,520 Closed
ARTA
104
A.R.T. Advisors
New York
– -$3.43M -165,478 Closed
ICM
105
ISZO Capital Management
New York
– -$2.78M -134,094 Closed
ACM
106
Atika Capital Management
New York
– -$2.06M -99,624 Closed
HI
107
HBK Investments
Texas
– -$1.34M -64,624 Closed
Fuller & Thaler Asset Management
108
Fuller & Thaler Asset Management
California
– -$1.15M -55,500 Closed
Two Sigma Advisers
109
Two Sigma Advisers
New York
– -$976K -47,098 Closed
DCM
110
Driehaus Capital Management
Illinois
– -$899K -43,416 Closed
Federated Hermes
111
Federated Hermes
Pennsylvania
– -$789K -38,068 Closed
TC
112
TFS Capital
Pennsylvania
– -$731K -35,302 Closed
Jacobs Levy Equity Management
113
Jacobs Levy Equity Management
New Jersey
– -$702K -33,900 Closed
GGHC
114
Gilder Gagnon Howe & Co
New York
– -$689K -33,244 Closed
SO
115
STRS Ohio
Ohio
– -$576K -27,800 Closed
VKH
116
Virtu KCG Holdings
New York
– -$470K -22,742 Closed
SCA
117
SAC Capital Advisors
Connecticut
– -$377K -18,176 Closed
PA
118
Perceptive Advisors
New York
– -$255K -12,306 Closed
VRS
119
Virginia Retirement Systems
Virginia
– -$255K -12,300 Closed
SIM
120
Spark Investment Management
New York
– -$231K -11,200 Closed
Group One Trading
121
Group One Trading
Illinois
– -$138K -8,550 Closed
LTFS
122
Ladenburg Thalmann Financial Services
Florida
– -$72.7K -4,500 -99%
DA
123
Denali Advisors
California
– -$56K -2,700 Closed
SFU
124
Stonehage Fleming (UK)
United Kingdom
– -$12K -562 Closed
Acadian Asset Management
125
Acadian Asset Management
Massachusetts
– -$11K -526 Closed
2 3 4
5
6

INSY Hedge Fund Activity: Q2 2014 in Review

99 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q2 2014, worth a combined $352M — down 5.4% from $372M a quarter earlier.

Fund positioning in INSY was balanced in Q2 2014: 28 funds opened new positions, 28 closed out, 39 added to existing stakes and 26 trimmed.

The largest buyer was Empyrean Capital Partners, opening a new position worth an estimated $25.9M. The largest seller was AllianceBernstein, cutting an estimated $21M.

  • 99 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q2 2014, unchanged from Q1 2014.
  • Funds reported $352M of Insys Therapeutics, Inc. stock for Q2 2014, down 5.4% quarter-over-quarter.
  • 28 funds opened new Insys Therapeutics, Inc. positions in Q2 2014 and 28 closed out, a net change of 0 holders.
  • The largest Insys Therapeutics, Inc. buyer in Q2 2014 was Empyrean Capital Partners, an estimated $25.9M added.
  • The largest Insys Therapeutics, Inc. seller in Q2 2014 was AllianceBernstein, an estimated $21M sold.

Based on aggregated 13F filings for Q2 2014.